Yayın:
Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab

Sadeleştirilmiş öğe sayfası
dc.contributor.authorAli Kaan Güren
dc.contributor.authorNazım Can Demircan
dc.contributor.authorÖzge Gümüşay
dc.contributor.authorEda Tanrıkulu Şimşek
dc.contributor.authorFatih Kemik
dc.contributor.authorCagla Karaoglu
dc.contributor.authorTaha Koray Şahin
dc.contributor.authorSalih Tünbekici
dc.contributor.authorKübra Akkaya
dc.contributor.authorMurad Guliyev
dc.contributor.authorBarış Gezici
dc.contributor.authorHasibe Bilge Gür
dc.contributor.authorDelyadil Karakaş
dc.contributor.authorAhmet Unlu
dc.contributor.authorO. Altunok
dc.contributor.authorİsmail Nazlı
dc.contributor.authorSedat Biter
dc.contributor.authorTuğba Kaya
dc.contributor.authorOzge Yetginoglu
dc.contributor.authorTuğçe Kübra Güneş
dc.contributor.authorLamia Şeker Can
dc.contributor.authorNargız Majidova
dc.contributor.authorNadiye Sever
dc.contributor.authorAysun Fatma Akkuş
dc.contributor.authorİsmail Oğuz Kara
dc.contributor.authorBanu Öztürk
dc.contributor.authorAdem Deligönül
dc.contributor.authorMuhammet Ali Kaplan
dc.contributor.authorElif Atağ
dc.contributor.authorİlhan Hacıbekiroğlu
dc.contributor.authorNebi Serkan Demirci
dc.contributor.authorFatih Selçuk Biricik
dc.contributor.authorDeniz Can Güven
dc.contributor.authorSercan Aksoy
dc.contributor.authorRukiye Arıkan
dc.contributor.authorMurat Sarı
dc.contributor.authorİbrahim Vedat Bayoğlu
dc.contributor.authorOsman Köstek
dc.contributor.orcid0000-0002-3562-5006
dc.contributor.orcid0000-0002-6236-9829
dc.contributor.orcid0000-0001-6085-1921
dc.contributor.orcid0000-0002-3590-0426
dc.contributor.orcid0000-0001-8804-7636
dc.contributor.orcid0000-0002-2981-8098
dc.contributor.orcid0000-0002-1053-0668
dc.contributor.orcid0000-0002-0684-8710
dc.contributor.orcid0000-0002-7917-2459
dc.contributor.orcid0000-0003-3838-1753
dc.contributor.orcid0000-0002-2575-5819
dc.contributor.orcid0000-0003-4963-2028
dc.contributor.orcid0000-0002-0333-7405
dc.contributor.orcid0000-0001-5943-889X
dc.contributor.orcid0000-0003-2688-1515
dc.date.accessioned2026-05-20T10:27:45Z
dc.date.issued2026-03-04
dc.identifier.doi10.1080/1750743x.2026.2662201
dc.identifier.endpage326
dc.identifier.issn1750-743X
dc.identifier.issue4
dc.identifier.openalexW7155072267
dc.identifier.startpage317
dc.identifier.urihttps://hdl.handle.net/11421/40026
dc.identifier.urihttps://doi.org/10.1080/1750743x.2026.2662201
dc.identifier.volume18
dc.language.isoen
dc.relation.ispartofImmunotherapy
dc.rightsrestrictedAccess
dc.subjectPembrolizumab
dc.subjectAdverse effect
dc.subjectBreast cancer
dc.subjectComplete response
dc.subjectPathological
dc.subjectImmune system
dc.subjectProspective cohort study
dc.subject.sdg3
dc.titleImmune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab
dspace.entity.typePublication

Dosyalar

Koleksiyonlar

Publications